- CEO
- Da Peng Gao
- Full Time Employees
- 2,649
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- A5 Rongjing East Street Beijing BE China 100176
- IPO Date
- Aug 25, 2017
- Business
- Joinn Laboratories (China) Co., Ltd. (603127.SS) provides preclinical and non-clinical contract research organization (CRO) services for drug development, including safety evaluation, pharmacology, toxicology, metabolism, and pharmacokinetics studies; clinical trial services encompassing phase I units, bioanalytical testing, and pharmacovigilance; and sales of research models such as rodents, non-human primates, disease models, and experimental animals. The company also offers evaluations for veterinary drugs, pesticides, medical devices, cell-based assays, biologics, gene therapy, and stem cell drugs, with operations spanning China (Beijing headquarters, subsidiaries in Suzhou, Chongqing, Wuzhou, Guangzhou, Shanghai) and the United States (Richmond, CA; Worcester, MA). Founded in 1995 and headquartered at No. 5A Rongjing East Street, Beijing Economic-Technological Development Zone, Joinn serves pharmaceutical, biotechnology, agricultural, and medical device clients globally, holding certifications including CNAS/ILAC-MRA, NMPA, US FDA, OECD GLP, Korean MFDS GLP, and AAALAC accreditation. Recent developments include sustained revenue growth in non-clinical studies (1.92 billion CNY in 2024) and overseas sales expansion (439 million CNY in 2024), alongside H1 2025 profitability recovery after prior challenges, board appointments in January 2025 (Chang Yun Yang, Jing Liang Gu, Fang Tian Ying), and ongoing enhancements to inhalation toxicology and biologics evaluation capabilities.